3D Cell Culture Market size was valued at USD 1 Bn. in 2021 and the total 3D Cell Culture revenue is expected to grow by 16 % from 2022 to 2029, reaching nearly USD 3.3 Bn.
3D Cell Culture Market Overview:3D cell culture is a laboratory-created environment. A three-dimensional cell culture environment allows biological cells to interact in all three dimensions with their surroundings. Cells grown in 3D cell culture exhibit cellular characteristics and behavior similar to cells found in living organisms. These cultures are primarily of two types: two-dimensional (2D) and three-dimensional (3D) (3D). Because of their availability, ease of environmental control, cell observation, and measurement, 2D cell cultures have been preferred since the advent of cell culture techniques. Growing cells in flat layers on a surface, on the other hand, does not accurately model the in-vivo state. In comparison to 2D cell culture, 3D cell culture allows biological cells to grow and interact with their surroundings in all three dimensions. Cells grown in three-dimensional cell culture models have been shown to be physiologically relevant. They have demonstrated advancements in a variety of biological mechanisms, including cell morphology, proliferation, differentiation, cell number monitoring, viability, migration, and invasion of tumor cells into surrounding tissues, response to stimuli, angiogenesis stimulation, drug metabolism, gene expression & protein synthesis, immune system evasion, and in-vivo relevance. Thus, 3D cell cultures are useful in studying and analyzing disease etiology, facilitating their adoption in the field of research. This rate of growth is primarily due to the advantages that 3D cell cultures have over conventional 2D cell cultures in cell-to-cell and cell-to-matrix interactions. Ongoing R&D efforts for drug discovery, development, and screening, as well as a preference for the use of 3D cell cultures in cancer research, are expected to drive the 3D cell culture market during the forecast period. Similarly, an increase in demand for organ transplantation is expected to boost the growth of the 3D cell culture market share.
Report Scope:The report covers market features, size, growth, segmentation, geographical breakdowns, market shares, trends, and plans for the business on both the demand and supply sides. Future aspects of the Market are mainly presented based on factors on which the companies contribute to the market estimation, key trends, and segmentation analysis. It covers effective business strategies, consumer preferences, governmental regulations, recent competitor actions, as well as future business prospects and market concerns. In-depth financial information about top manufacturers, such as year-after-year sales, revenue growth, CAGR, production cost analysis, and value chain structure, is highlighted in the Single-use 3D Cell Culture Market study. To know about the Research Methodology :- Request Free Sample Report
3D Cell Culture Market Dynamics:To generate 3D organotypic structures to penetrate the 3D Cell Culture market 3D cultures are widely used in studies that require in vivo model systems to analyze the effects of a foreign drug on body tissues and organs because they can closely mimic a typical morphology and microarchitecture of organs. Additionally, the use of biomimetic tissue constructs to generate 3D organotypic structures compelled a large number of research organizations to adopt 3-dimensional cell culture techniques. Furthermore, the use of 3D tissue-engineered models for Covid-19, cancer, and other clinical disorders has emerged as a viable alternative to traditional approaches. When compared to 2D techniques, this also shows great promise in terms of providing a relatively simple and inexpensive in vitro tumor-host environment. The 3D cell culture market is expected to benefit significantly from the high utility of 3-dimensional models for research on Covid-19 and respiratory diseases. Airway and air-liquid interface organoids have been used as tools for antiviral drug development and discovery, as well as experimental virology platforms to study SARS-CoV-2 immune responses and infectivity. Scaffold-based and scaffold-free techniques enable the bio-fabrication of realistic models that can be used to develop novel Covid-19 therapeutics and vaccines. Growing importance of developing alternatives to animal testing Animal models are commonly used in cell biology research to study human diseases. However, there are several drawbacks to this, including the possibility of animal harm and difficulties in ensuring result accuracy due to differences in species, disease mechanisms, and drug responses. To address these issues, various institutes are working on alternative drug development methods. Some European regulations that strongly encourage the replacement of animal testing include the Directive on the Protection of Animals Used for Scientific Purposes (2010/63), the Cosmetic Products Regulation (1223/2009), REACH (2007/2006), and Classification, Labeling, and Packaging (CLP) (1272/2008). Moreover, the Canadian Centre for Alternatives to Animal Methods, the Canadian Centre for the Validation of Alternative Methods, Cruelty-Free International, and the Fund for the Replacement of Animals in Medical Expendents are all opposed to the use of animal-based models in research. Market Restraints: Inconsistency in 3D cell culture products The use of scaffold-based 3D cell cultures has broadened the field of research. However, the presence of multiple growth factors in scaffolds causes batch-to-batch variability, which interferes with biological and pharmacological studies of signaling pathways. To address this issue, growth-factor-reduced scaffolds such as Matrigel Matnx have been developed (Coming). Although the cells grown on scaffolds with reduced growth factors exhibited phenotypes similar to those grown on scaffolds with high growth factors, the proliferation rate was extremely high. Furthermore, cells grown on low-growth-factor scaffolds are not suitable for human implantation. This emphasizes the importance of materials that provide the natural functionality of ECM as well as the ability to specify biological and material properties. Scaffolds made of synthetic materials, such as synthetic peptides, are expected to overcome this barrier soon; however, lack of consistency will remain a major 3D cell culture market challenge until their introduction. Market Opportunity: The emergence of 3D cell culture using microfluidics Microfluidics in 3D cell culture has recently enabled the development of microenvironments that support tissue differentiation and replicate the tissue-tissue interface, spatiotemporal chemical gradients, and mechanical macro environments of living organs. This organ-on-a-chip model allows for the study of human physiology in an organ-specific context, allowing for the development of in vitro disease models and ultimately serving as a replacement for animal models in drug development and toxicity testing. To strengthen the 3D cell culture market position, key players in this market are forming partnerships and collaborations with pharmaceutical companies. This strategy allows market participants to assess the performance of the various organs-on-chips. Drug development and other pharmaceutical research opportunities In November 2021, for example, CN Bio announced a research collaboration aimed at validating novel organ-on-a-chip infection models. MIMETAS and Roche collaborated in July 2021 to create human disease models to characterize novel compounds in inflammatory bowel disease (BD) and B virus infections (HBV). Recent Advances in 3D cell culture to boost the market Significant factors driving 3D cell culture market growth include the introduction of new products and the widespread use of 3D protocols in biological research. For example, in December 2020, eNUVIO Inc., a biotechnology company based in Canada, will release the EB-Plate, a completely reusable microplate for 3D cell culture. This is expected to reduce single-use plastic waste, improve the utility of 3-dimensional microplates, and accelerate the zero-waste movement in laboratories. Similarly, standard 2D analysis methods can be easily applied to Lonza's RAFT 3D cultures. Many laboratories around the world have adopted these novel technologies because they do not necessitate many changes to existing 2D culture methods. Lonza has also developed 3D cell culture models to improve in vitro hepatotoxicity testing in areas such as hepatic signaling pathways and drug-induced liver injury.
3D Cell Culture Market Segment Analysis:Based on Technology, Scaffold-based technology had the highest revenue share of more than 72.96% in 2021. The use of hydrogels as scaffolds in 3-dimensional cell culture research allows for the incorporation of sophisticated biochemical and mechanical indicators as a mirror of the native extracellular matrix. Additionally, the introduction of new products and the growing demand for hydrogel advancements to provide robust platforms for studying human and cellular physiology are expected to drive market growth in the forecast years. Researchers from China's Southern University of Science and Technology developed a method for 3D printing highly stretchable hydrogels in January 2021. This contributes to overcoming the limitations of hydrogel-polymer-based scaffold performance and functionality. Adocia, a Paris-based biopharmaceutical company, developed a hydrogel scaffold for cell therapy of Type 1 diabetes in January 2021. The growing popularity and awareness of nanotechnology in biomedical research is expected to create potential growth opportunities for nanofiber-based scaffolds, thereby increasing sales and demand for the scaffold-based technology. Magnetic levitational assembly of 3D tissue constructs is a new and rapidly expanding label-free approach to tissue engineering. Over the forecast period, this is expected to propel the scaffold-free segment with the fastest CAGR. Based on the Application, In 2020, the cancer segment dominated the market with a 35.56% revenue share. The use of spheroids as model systems in the development of anticancer therapies drives R&D in this segment. Furthermore, the use of 3-dimensional cellular models for the study of cancer biology in preclinical testing and screening is expected to increase revenue generation in this segment. A research study published in January 2021 reported the creation of polysaccharide hydrogel-based 3D printed tumor models that can be used for high throughput screening of anti-cancer drugs. The researchers' goal with this study was to create a hydrogel that effectively mimics the tumor microenvironment while also exhibiting appropriate biocompatibility, rheological properties, and printability. Such advancements lead to an increase in the use of scaffold-based cancer treatments. During the forecast period, the stem cell research segment is expected to grow at the fastest CAGR. The rise in applications of 3D cell culture platforms for regenerative medicine is expected to drive segment growth. Histogen, Inc., a regenerative medicine company, merged with Conatus Pharmaceuticals, Inc. in January 2020. The latter has a robust pipeline of novel clinical candidates, including an extracellular matrix scaffold aimed at treating articular cartilage conditions. Based on the End-use, In 2021, the biotechnology and pharmaceutical industries segment generated the highest revenue share of more than 48%. In comparison to 2D cell culture, 3D cell cultures have advantages in terms of optimal oxygen and nutrient gradients, non-uniform exposure of cells within a spheroid to a drug, and realistic cell-to-cell interactions. These factors make 3D cell cultures more suitable for drug discovery and development, fueling demand. Factors such as the urgent need for more rapid and accurate diagnostic services, as well as the advantages of 3D models over 2D models in providing detailed physiological information, are driving the growth of the hospitals and diagnostic centers segment. Furthermore, the presence of diagnostic centers like Kiyatec, which are actively involved in providing 3D models for advanced research, is expected to drive segment growth in the forecast years. Academic institutes and industrial laboratories are also expected to contribute to this market's growing share. Institutes' workshops and training programs on 3D cell culture systems are expected to drive demand for 3D cell culture products and systems over the forecast period.
3D Cell Culture Market Regional Insights:North America dominated the market and is expected to continue to do so. The overall 3D cell culture market in North America is dominated by the United States, which is the market's largest contributor. The United States is focusing on R&D and has made significant investments in 3D cell culture research in recent years. As a result, the country has made technological advances. Many Americans are among the top patent applicants in the 3D cell culture domain. American applicants typically develop their technologies both in the United States and in Asia. In recent years, there has also been significant investment in the bioengineering sector in the United States. Bioengineering also includes 3D cell culture research. According to the National Institute of Health, total investment in various bioengineering technologies is expected to reach USD 5,654 in 2020, up from USD 5,095 in 2019. These factors have increased the size of the US 3D cell culture market. Furthermore, there is a need to mimic intricate elements of human physiology, pathology, and medication reactions in vitro. The region's demand for organ transplantation is expected to drive up demand for 3D cell cultures. According to the Canadian Institute for Health Information, a total of 3,014 transplant procedures (all organs) will be performed in Canada (including Quebec) in 2021, a 45% increase from 2010. As a result, all of the aforementioned factors are expected to boost the market in the region over the forecast period.
3D Cell Culture Market Scope: Inquire before buying
3D Cell Culture Market Report Coverage Details Base Year: 2021 Forecast Period: 2022-2029 Historical Data: 2017 to 2021 Market Size in 2021: US $ 1 Bn. Forecast Period 2022 to 2029 CAGR: 16% Market Size in 2029: US $ 3.3 Bn. Segments Covered: by Technology • Scaffold-based
o Hydrogels o Polymeric Scaffolds o Micro-patterned Surface Microplates o Nanofiber-based Scaffolds• Scaffold-free
o Hanging Drop Microplates o Microfluidic 3D Cell Culture o Spheroid Microplates with ULA coating o Magnetic Levitation & 3D Bioprinting o Bioreactors
by Application • Cancer • Tissue Engineering & Immunohistochemistry • Drug Development • Stem Cell Research • Others by End-use • Biotechnology and Pharmaceutical Industries • Research Laboratories and Institutes • Hospitals and Diagnostic Centers • Others
3D Cell Culture Market by Region• North America • Europe • Asia Pacific • South America • Middle East and Africa
3D Cell Culture Market Key Players are:• Thermo Fisher Scientific (US) • Corning Incorporated (US) • Pall Corporation (US) • Hamilton Company (US) • Avantor, Inc. (US) • 3D Biotek LLC (US) • REPROCELL Inc. (US) • Emulate Inc. (US) • InSphero (US) • Synthecon Incorporated (US) • Lena Biosciences (US) • Advanced BioMatnx Inc (US) • Agilent Technologies, Inc. (US) • Advanced Instruments, LLC (US) • Pall Corporation (US) • Hamilton Company (US) • Merck Group (Germany) • TissUse GmbH (Germany) • PromoCell GmbH (Germany) • CN Bio Innovations Ltd (UK) • Kirkstall Ltd (UK) • Lonza Group AG (Switzerland) • Tecan Group Ltd. (Switzerland) • QGel SA (Switzerland) • MIMETAS BV (Netherlands) • UAB Ferentis (Lithuania) • Hitachi, Ltd. (Japan) Frequently Asked Questions: 1] What is a 3D cell culture model? Ans. 3D cell culture is a cultural environment that allows cells to grow and interact in three dimensions with the surrounding extracellular framework. This is in contrast to traditional 2D cell cultures, which grow cells in a flat monolayer on a plate. 2] How is 3D cell culture done? Ans. To allow for growth in all directions, 3D cells can be cultured within a supporting scaffold. Scaffolds that are commonly used include: Hydrogels are polymeric materials that absorb and retain water due to a network of crosslinked polymer chains. 3] What is a scaffold in 3D cell culture? Ans. Growing cells on structural scaffolds, which are typically made of biopolymers arranged to mimic the physiological extracellular matrix, is a well-established method for 3D cell culture (ECM). These scaffolds are typically designed as inserts that can be easily incorporated into standard cell culture workflows. 4] Which is the most suitable technique for growing a cell line in the form of 3D culture? Ans. 3D culture technique based on scaffolding. Scaffolds, as previously stated, can be useful supports for 3D cell culture. Scaffolds facilitate oxygen, nutrient, and waste transportation due to their porosity. Cells can thus proliferate and migrate within the scaffold web, eventually adhering to it. 5] How does cell culture work? Ans. Cell culture is the artificial, controlled growth of cells from an animal or plant. Cells are extracted either directly from the organism and disaggregated before cultivation, or from a previously established cell line or cell strain.
1. Global 3D Cell Culture Market Size: Research Methodology 2. Global 3D Cell Culture Market Size: Executive Summary 2.1. Market Overview and Definitions 2.1.1. Introduction to Global 3D Cell Culture Market Size 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global 3D Cell Culture Market Size: Competitive Analysis 3.1. MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2. Consolidation in the Market 3.2.1 M&A by region 3.3. Key Developments by Companies 3.4. Market Drivers 3.5. Market Restraints 3.6. Market Opportunities 3.7. Market Challenges 3.8. Market Dynamics 3.9. PORTERS Five Forces Analysis 3.10. PESTLE 3.11. Regulatory Landscape by region • North America • Europe • Asia Pacific • Middle East and Africa • South America 3.12. COVID-19 Impact 4. Global 3D Cell Culture Market Size Segmentation 4.1. Global 3D Cell Culture Market Size, by Technology (2021-2029) • Scaffold-based • Hydrogels • Polymeric Scaffolds • Micro-patterned Surface Microplates • Nanofiber-based Scaffolds • Scaffold-free • Hanging Drop Microplates • Microfluidic 3D Cell Culture • Spheroid Microplates with ULA coating • Magnetic Levitation & 3D Bioprinting • Bioreactors 4.2. Global 3D Cell Culture Market Size, by Application (2021-2029) • Cancer • Tissue Engineering & Immunohistochemistry • Drug Development • Stem Cell Research • Others 4.3. Global 3D Cell Culture Market Size, by End-use (2021-2029) • Biotechnology and Pharmaceutical Industries • Research Laboratories and Institutes • Hospitals and Diagnostic Centers • Others 5. North America 3D Cell Culture Market (2021-2029) 5.1. North America 3D Cell Culture Market Size, by Technology (2021-2029) • Scaffold-based • Hydrogels • Polymeric Scaffolds • Micro-patterned Surface Microplates • Nanofiber-based Scaffolds • Scaffold-free • Hanging Drop Microplates • Microfluidic 3D Cell Culture • Spheroid Microplates with ULA coating • Magnetic Levitation & 3D Bioprinting • Bioreactors 5.2. North America 3D Cell Culture Market Size, by Application (2021-2029) • Cancer • Tissue Engineering & Immunohistochemistry • Drug Development • Stem Cell Research • Others 5.3. North America 3D Cell Culture Market Size, by End-use (2021-2029) • Biotechnology and Pharmaceutical Industries • Research Laboratories and Institutes • Hospitals and Diagnostic Centers • Others 5.4. North America Semiconductor Memory Market, by Country (2021-2029) • United States • Canada • Mexico 6. European 3D Cell Culture Market (2021-2029) 6.1. European 3D Cell Culture Market, by Technology (2021-2029) 6.2. European 3D Cell Culture Market, by Application (2021-2029) 6.3. European 3D Cell Culture Market, by End-use (2021-2029) 6.4. European 3D Cell Culture Market, by Country (2021-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific 3D Cell Culture Market (2021-2029) 7.1. Asia Pacific 3D Cell Culture Market, by Technology (2021-2029) 7.2. Asia Pacific 3D Cell Culture Market, by Application (2021-2029) 7.3. Asia Pacific 3D Cell Culture Market, by End-use (2021-2029) 7.4. Asia Pacific 3D Cell Culture Market, by Country (2021-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa 3D Cell Culture Market (2021-2029) 8.1. Middle East and Africa 3D Cell Culture Market, by Technology (2021-2029) 8.2. Middle East and Africa 3D Cell Culture Market, by Application (2021-2029) 8.3. Middle East and Africa 3D Cell Culture Market, by End-use (2021-2029) 8.4. Middle East and Africa 3D Cell Culture Market, by Country (2021-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America 3D Cell Culture Market (2021-2029) 9.1. South America 3D Cell Culture Market, by Technology (2021-2029) 9.2. South America 3D Cell Culture Market, by Application (2021-2029) 9.3. South America 3D Cell Culture Market, by End-use (2021-2029) 9.4. South America 3D Cell Culture Market, by Country (2021-2029) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1. Thermo Fisher Scientific (US) 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Corning Incorporated (US) 10.3. Pall Corporation (US) 10.4. Hamilton Company (US) 10.5. Avantor, Inc. (US) 10.6. 3D Biotek LLC (US) 10.7. REPROCELL Inc. (US) 10.8. Emulate Inc. (US) 10.9. InSphero (US) 10.10. Synthecon Incorporated (US) 10.11. Lena Biosciences (US) 10.12. Advanced BioMatnx Inc (US) 10.13. Agilent Technologies, Inc. (US) 10.14. Advanced Instruments, LLC (US) 10.15. Pall Corporation (US) 10.16. Hamilton Company (US) 10.17. Merck Group (Germany) 10.18. TissUse GmbH (Germany) 10.19. PromoCell GmbH (Germany) 10.20. CN Bio Innovations Ltd (UK) 10.21. Kirkstall Ltd (UK) 10.22. Lonza Group AG (Switzerland) 10.23. Tecan Group Ltd. (Switzerland) 10.24. QGel SA (Switzerland) 10.25. MIMETAS BV (Netherlands) 10.26. UAB Ferentis (Lithuania) 10.27. Hitachi, Ltd. (Japan)